https://seekingalpha.com/article/4302900-regenxbio-inc-rgnx-ceo-kenneth-mills-q3-2019-results-earnings-call-transcript?source=feed_sector_healthcare
Nov 05, 2019 - REGENXBIO, Inc. (NASDAQ:RGNX) Q3 2019 Earnings Conference Call November 5, 2019 04:30 PM ET Company Participants Patrick Christmas - Senior Vice President and General Counsel Kenneth Mills - President
0
sa:-7971215481379657624
0
https://www.fool.com/earnings/call-transcripts/2019/11/05/regenxbio-inc-rgnx-q3-2019-earnings-call-transcrip.aspx?source=iedfolrf0000001
Nov 05, 2019 - RGNX earnings call for the period ending September 30, 2019.
0
fool:-3086873459907447968
0
http://www.zacks.com/stock/news/605253/regenxbio-rgnx-reports-q3-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-605253
Nov 05, 2019 - Regenxbio (RGNX) delivered earnings and revenue surprises of -3.30% and 97.18%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
zc:-6403598949284623674
0
http://www.zacks.com/stock/news/565788/ultragenyxs-rare-nda-for-lc-faod-drug-accepted-by-fda?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-565788
Oct 15, 2019 - Ultragenyx (RARE) announces FDA's acceptance of the NDA for UX007 for the treatment of LC-FAOD.
zc:5028765660576164555
0
https://www.fool.com/investing/2019/10/11/big-pharma-has-mad-love-for-these-2-biotechs.aspx?source=iedfolrf0000001
Oct 11, 2019 - These companies' collaborations with bigger businesses validates their science -- and paves the way for future revenues and profits.
0
fool:-6669590583944131649
0
http://www.zacks.com/stock/news/557772/wet-amd-space-in-focus-new-drug-approvals-key-advancements?cid=CS-ZC-FT-analyst_blog|industry_focus-557772
Oct 10, 2019 - The FDA approval of Novartis' Beovu for wet AMD brings this space to focus. Let us assess the recent key developments in the area.
zc:697143892974459051
0
http://www.zacks.com/stock/news/545745/ultragenyx-gets-fda-approval-for-label-expansion-of-crysvita?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-545745
Oct 02, 2019 - Ultragenyx (RARE) and partner Kyowa Kirin get FDA approval for the label expansion of Crysvita in pediatric patients with X-linked hypophosphatemia.
zc:-4957131818022530406
0
http://www.zacks.com/stock/news/501422/ultragenyx-genetx-get-orphan-drug-status-for-gtx-102-from-fda?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-501422
Sep 04, 2019 - The FDA grants Orphan Drug and Rare Pediatric Disease designations to Ultragenyx (RARE) and partner GeneTx Biotherapeutics' GTX-102 for the treatment of Angelman Syndrome.
zc:6883586330048191801
0
https://www.fool.com/investing/2019/05/24/approval-of-a-game-changing-gene-therapy-for-sma-d.aspx?source=iedfolrf0000001
May 24, 2019 - A $2.1 million price tag could make Zolgensma a blockbuster medicine for these companies.
0
fool:-7210121496792688668
0
https://seekingalpha.com/article/4261299-regenxbio-inc-rgnx-ceo-kenneth-mills-q1-2019-results-earnings-call-transcript?source=feed_sector_healthcare
May 07, 2019 - Regenxbio, Inc. (NASDAQ:RGNX) Q1 2019 Earnings Conference Call May 07, 2019, 16:30 ET Company Participants Patrick Christmas - SVP & General Counsel Kenneth Mills - CEO, President & Director S
0
sa:-6245920448094876437
0